Ovulation dropped by 75% and more in women taking certain over-the-counter and prescription pain meds.
Certain widely used pain relievers can have a harmful effect on a woman’s fertility and should be used with caution by women wishing to start a family. One over-the-counter (OTC), non-steroidal anti-inflammatory drug (NSAID) has been found to reduce fertility in women; two other prescription pain relievers also appear to have this effect.
Naproxen, known by the brand names Aleve, Naprosyn, and many others, and two additional pain relievers strongly interfered with ovulation in a recent study of women with back pain.
NSAIDs are among the world’s most commonly used drugs — about 30 million people take them every day.
The drugs looked at in the study were naproxen, diclofenac (marketed as the drugs Voltaren, Arthrotec, and Dyloject among others) and etoricoxib (marketed under many trade names).
In the United States, naproxen is available OTC, while diclofenac requires a prescription and etoricoxib does not have FDA approval. But worldwide, diclofenac may be the most popular NSAID, while etoricoxib is used in over 80 countries.
Ovulation occurred 100% of the time in women who weren’t taking any of the drugs, it fell to 25% in women taking naproxen, 27% in women taking etoricoxib and 6% in women taking diclofenac.
The study looked at 39 women who had visited a clinic at Baghdad Hospital for minor back pain. Each was given one of the three drugs for ten days, starting at day 10 of their menstrual cycle. Doses were 500 mg twice a day for naproxen, 100 mg once a day for diclofenac and 90 mg once a day for etoricoxib. An additional group of women who were not given any of the three drugs served as controls.
Blood samples were taken at the start of study and at day 20 for hormonal analysis. Ultrasonography was used to monitor the progress of the dominant (largest) egg follicle. Tests showed that the drugs caused a significant decrease in the level of the hormone progesterone. The dominant egg follicle also tended not to rupture in women who were taking the drugs, thus preventing the release of the egg.
At the end of the treatment period, the dominant follicle remained unruptured in 75%, 25% and 33% of patients receiving diclofenac, naproxen and etoricoxib respectively.
The researchers stress that these effects were seen after only 10 days of drug use. Many women with arthritis or other painful conditions may take these drugs on a regular basis for far longer than 10 days, without any awareness of their possible effect on their ability to have children.
On a brighter note, these findings may help point the way to development of an emergency contraceptive that’s safer than the ones currently in use.
The study was presented at EULAR Rome 2015, the Annual European Congress of Rheumatology, held June 10-13.
June 17, 2015